http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PE-20212110-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9008466a40998f8be8e54cd3aceb10a2 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J3-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2014-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a533fc49639fab21d83e5f995de7aeca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3903bf5e75f5ad632c0d78e5b33246a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_993ecd84009a982adc1e94cd010f7bf9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d717650decf4bd29c3505ee8dd7be7c0 |
| publicationDate | 2021-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PE-20212110-A1 |
| titleOfInvention | DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION |
| abstract | Related to a process for the preparation of a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic to be delivered by a dry powder inhaler (DPI); wherein said process comprises the steps: i) preselecting the excipient particles and the additive particles of fraction a) with a particle size in which at least 90% of all the particles have a volume diameter of less than 12 microns, and the volume median diameter of said particles is 3 to 7 microns; ii) preparing the fine particle fraction a), by co-mixing the excipient particles and the additive particles in a high energy apparatus for a period of less than 20 minutes; and iii) mixing said fraction of fine particles a), said fraction of coarse particles b) and all the micronized active ingredients. It also refers to a formulation comprising: a) a fraction of fine particles, 90 to 99.5% by weight of micronized particles of a physiologically acceptable excipient and 0.5 to 10% by weight of magnesium stearate, b) a fraction of coarse particles: physiologically acceptable excipient, where the ratio between fine particles a) and coarse particles b) is 1:99 and 30:70% by weight; c) a combination of micronized particles of glycopyrronium bromide, beclomethasone dipropionate and formoterol fumarate dihydrate as active ingredients. |
| priorityDate | 2013-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.